Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Sponsor
West China Hospital
Study ID
NCT05640609
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Stomach Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The median survival time of first-line chemotherapy for advanced gastric cancer is about one year, and the treatment is still facing the bottleneck. This is a one-arm, open and prospective phase II clinical study. Recruit patients who have been diagnosed with advanced or metastatic adenocarcinoma of the stomach and gastroesophageal junction and have not received systematic treatment.

Key Dates

First listed
Dec 7, 2022
Start date
Mar 10, 2023
Status verified
May 2023
Primary completion
Nov 1, 2024
Completion
Nov 1, 2026

Study Design

Enrollment
57 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Capeox regimen combined with Sintilimab and Bevacizumab
    Capeox regimen combined with Sintilimab and Bevacizumab

Primary Outcome Measure

the appropriate dose of Bevacizumab [ Time Frame: 1.5-3months ]

Central Contacts